Australian Dementia Research Forum

DAY 1 |

Highlights of the Day in Brief
Presenter Summaries:
Symposium 3. Novel Therapy in Alzheimer’s Disease

Highlights from a general practice perspective
Delegate: Dr Stephanie Daly

Highlights from a geriatric medicine perspective
Delegate: Associate Professor Michael Woodward AM

Blood-based biomarkers in general practice

Highlights from a geriatric medicine perspective
Delegate: Associate Professor Paul Yates

Highlights from a neurology and nuclear medicine perspective
Delegate: Professor Christopher Rowe

Symposium 3: Novel Therapy in Alzheimer’s Disease

Moderator – Professor Ralph Martins AO

Speakers highlight key points from their presentations

Professor Amy Brodtmann:
Clinical Relevance of Donanemab Treatment

Associate Professor Paul Yates:
TRAILBLAZER-ALZ 6 Primary Outcome: Modified Titration of Donanemab Reduces ARIA Risk and Maintains Amyloid Reduction

Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330: 512-527. Available here (accessed June 2025).

Dr Andrew Gleason:
Screening and Baseline Results from the Donanemab Phase 3 Study in Preclinical Alzheimer’s Disease

Additional information

Dr Stéphane Epelbaum:
Efficacy and Safety of Donanemab, A Novel Amyloid-Targeting Therapy

Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med 2021; 384: 1691-1704. Available here (accessed June 2025).
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330: 512-527. Available here (accessed June 2025).

Click here to learn more about our delegates and speakers

Not a registered user of our websites?

Sign up for access here »